Clinical trial NCT00103779: A Safety Study of SGN-40 in Patients With Non-Hodgkin's Lymphoma
Official title: A Phase I, Multi-Dose Study of SGN-40 (Anti-huCD40 mAb) in Patients With Non-Hodgkin's Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Non-Hodgkin Lymphoma
Keywords: Antigens, CD40
Antibody, Monoclonal
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Hematologic Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoproliferative Disorders
Lymphoma
Lead sponsor: Seagen Inc.
Sponsor class: INDUSTRY
Collaborators: name: Genentech, Inc.
First posted: 2005-02-15
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label, multi-dose, Phase I, dose escalation study to define the safety profile and preliminary anti-tumor activity of SGN-40 in patients with refractory or recurrent non-Hodgkin B-cell lymphomas.

Detailed description: A minimum of 3 patients will be entered into each dose-level cohort for 5 weeks. A dose-escalation schema will be employed in cohorts. The initial dose starts at 1 mg/kg on Day 1 and 4 followed by 2mg/kg on Day 8. Dose escalation will occur on weeks 3-5 with a maximum weekly dose of 8 mg/kg. Patients who meet criteria of at least partial response will be eligible for additional 4 weekly doses at highest dose tolerated.

Eligibility criteria: Inclusion Criteria:

* Patients must have a histological diagnosis of B cell non-Hodgkin's lymphoma, including diffuse large B-cell, mantle cell, follicular, small lymphocytic, and marginal zone lymphoma by the World Health Organization criteria.
* Patients must have an archived paraffin or fresh tumor specimen available for immunohistologic evaluation of CD40, CD20, \& CD79a.
* Patients must have relapsed lymphoma and must have failed frontline chemotherapy.
* Patients who have not received autologous stem cell transplant must have refused or be ineligible for it.
* Patients must have completed radiotherapy, chemotherapy, and/or treatment with investigational anti-cancer agents 4 weeks prior to registration. Patients must have completed any monoclonal antibody treatment, including rituximab, 6 months prior to registration.
* Patients must have completed autologous bone marrow transplant 4 months prior to registration.
* Patient must have at least one site of measurable disease defined by unidimensional lesion ≥ 2 cm by conventional CT scan.
* Patients must have an ECOG performance status ≤ 2 and a life expectancy \> 3 months.
* Patients must have the following required baseline laboratory data:

  * Platelet count ≥ 75,000/mm3,
  * Hemoglobin ≥ 9.0 g/dL,
  * Absolute neutrophil count ≥ 1,250/mm3,
  * ALT/AST ≤ 2.5 times ULN,
  * Total bilirubin ≤ 1.5 times ULN,
  * Creatinine \< 1.5 mg/dL,
* Females of childbearing potential must have a negative serum β-hCG pregnancy test result within 3 days prior to the first dose of SGN-40 and must agree to use an effective contraceptive method during the course of the study and for 6 months following the last dose of study drug.
* If a deep venous thrombosis or other vascular even has required medical or surgical intervention in the past year, patients must either be on stable dose of anticoagulant therapy for at least 3 weeks or have completed anticoagulant therapy at least 3 months prior to registration with radiographic confirmation that thrombosis is resolved.
* Patients must be at least 18 years of age.
* Patients must be available for periodic blood sampling, study-related assessments and management of toxicity at the treating institution.

Exclusion Criteria:

* Patients with history or clinical evidence of leptomeningeal or central nervous system (CNS) lymphoma.
* Patients with a documented history within 6 months of registration of a cerebral vascular event, myocardial infarction, deep venous thrombosis or other vascular event that has required medical or surgical intervention. Patients must have completed anticoagulant therapy at least 3 months prior to registration. Prophylactic anticoagulant therapy for indwelling catheters is acceptable.
* Patients who have received an allogeneic stem cell transplant.
* Patients who have had major surgery within 4 weeks prior to registration.
* Patients with a known hypersensitivity to recombinant proteins or any excipient contained in the drug formulation.
* Patients with a history of another primary malignancy that has not been in remission for at least 5 years (non-melanoma skin cancer and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on PAP smear are exempt from the five year limit).
* Patients with any active systemic viral, bacterial, or fungal infection within four weeks prior to registration.
* Patients with known positivity for HIV, hepatitis B or hepatitis C infection.
* Patients with a history of significant chronic or recurrent infections requiring treatment.
* Patients with a history of migraines or severe headaches requiring medical therapy within 12 months of enrollment.
* Patients on systemic steroids who have not been on a stable daily dose (not exceeding 10 mg prednisone or equivalent) during 4 weeks prior to the first dose of SGN 40.
* Patients who are pregnant or breastfeeding.
* Patients with any serious underlying medical condition that would impair their ability to receive or tolerate the planned treatment.
* Patients with dementia or altered mental status that would preclude the understanding and/or rendering of informed consent.

Primary outcomes:
measure: Adverse events and lab abnormalities.
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
city: Stanford
country: United States
facility: Stanford University
state: California
city: Miami
country: United States
facility: University of Miami
state: Florida
city: New York
country: United States
facility: Cornell University
state: New York
city: Houston
country: United States
facility: University of Texas MD Anderson Cancer Center
state: Texas
Study officials:
affiliation: Seagen Inc.
name: Jonathan Drachman, MD
role: STUDY_DIRECTOR
References:
citation: Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol. 2009 Sep 10;27(26):4371-7. doi: 10.1200/JCO.2008.21.3017. Epub 2009 Jul 27.